On January 8, 2024, Atara Biotherapeutics, Inc. announced that the employment of Manher (AJ) Joshi, the Company?s Executive Vice President, Chief Medical Officer, would terminate effective as of February 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5299 USD | -2.91% | -20.91% | +3.33% |
May. 09 | Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M | MT |
Apr. 01 | Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.33% | 63.81M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ATRA Stock
- News Atara Biotherapeutics, Inc.
- Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024